Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02738918 | Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study. | PHASE2 | COMPLETED | 51 | — | — | Dec 1, 2014 | Sep 18, 2017 | Jul 5, 2019 | 1 | France |
| Arm | Type | Description |
|---|---|---|
| Nulojix | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Nulojix (Belatacept) | DRUG | Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12 |
Inclusion Criteria: 1. Signed Written Informed Consent a) Before any study procedures are performed, subjects will have the details of the study described to them, and they will be given a written informed consent document to read. Then, if subjects consent to participate in the study, they wil...